The FDA published final guidance on ICH M11 CeSHarP in May 2026, establishing a harmonized standard for clinical trial protocol structure, format, and electronic exchange. This follows EMA's December 2025 adoption and caps an eight-year development process. The guidance includes three components: a rationale document, a standardized protocol template with fixed section headings, and a technical specification defining machine-readable data fields with coded identifiers.

For sites, the immediate impact centers on protocol consistency. Before M11, every sponsor used different templates, forcing sites to navigate varying formats across studies. The new standard creates uniform structure, though adoption timelines differ by region and the guidance remains nonbinding for FDA submissions.

The timing matters because protocol complexity is rising. Recent Tufts data shows amendments per protocol jumped to 3.3 from 2.1 in 2015, with approval cycles averaging 260 days and Phase III amendment costs reaching $535,000. While M11 addresses format variability rather than amendment frequency directly, standardized structure could ease downstream reconciliation across EDC, safety reporting, and regulatory systems. Sites should expect a transition period as sponsors adopt the template and develop new authoring workflows for coded protocol fields.